Surgery in malignant pancreatic neuroendocrine tumors

Journal of Surgical Oncology

Volumn 96, Issue 5, 2007, Pages 397-403

  Nguyen, Scott Q ^a   Angel, Luz P ^a   Divino, Celia M ^a   Schluender, Stefanie ^a   Warner, Richard R P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Islet cell carcinoma; Neuroendocrine tumors; Pancreas

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PANCREATECTOMY; PANCREATIC NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RADIOTHERAPY, ADJUVANT; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 34948823276     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20824     Document Type: Article

References (28)

1. Eriksson B, Oberg K: Neuroendocrine, tumors of the pancreas. Br J Surg 2000;87:129-131.
2. Grant CS: Surgical management of malignant islet cell tumors. World J Surg 1993;17:498-503.
3. Mantke R, Manger T, Schulz HU, et al.: Multimodal treatment of neuroendocrine tumors of the pancreas and the ampulla of vater. Dig Surg 1999;16:145-151.
4. Solorzano CC, Lee JE, Pisters PW, et al.: Nonfunctioning islet cell carcinoma of the pancreas: Survival results in a contemporary series of 163 patients. Surgery 2001;130:1078-1085.
5. Lo CY, van Heerden JA, Thompson GB, et al.: Islet cell carcinoma of the pancreas. World J Surg 1996;20:878-883.
6. Chu QD, Hill HC, Douglass HO Jr, et al.: Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Onc 2002;9:855-862.
7. Grama D, Eriksson B, Martensson H, et al.: Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992;16:632-639.
8. Phan GQ, Yeo CF, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 1998;2:473-482.
9. Norton JA, Warren RS, Kelly MG, et al.: Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 2003;134:1057-1065.
10. Sarmiento JM, Heywood G, Rubin J, et al.: Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003;197:29-37.
11. Florman S, Toure B, Kim L, et al.: Liver transplantation for neuroendocrine tumors. J Gastrointest Surg 2004;8:208-212.
12. Bilchik AJ, Sarantou T, Foshag LJ, et al.: Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997;122:1040-1047.
13. Henn AR, Levine EA, McNulty W, et al.: Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. Am J Rad 2003;181:1005-1010.
14. Kalra MK, Maher MM, Mueller PR, et al.: State-of-the-art imaging of pancreatic neoplasms. Br J Rad 2003;76:857-865.
15. Schillaci O, Spanu A, Scopinaro F, et al.: Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2003;44:359-368.
16. Anderson MA, Carpenter S, Thompson NW, et al.: Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271-2277.
17. Hiramoto JS, Feldstein VA, LaBerge JM, et al.: Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 2001;136:1020-1026.
18. Jaroszewski DE, Schlinket RT, Thompson GB, et al.: Laparoscopic localization and resection of insulinomas. Arch Surg 2004;139:270-274.
19. Sundin A, Eriksson B, Bergstrom M, et al.: PET in the diagnosis of neuroendocrine tumors. Ann NY Acad Sci 2004;1014:246-257.
20. Becherer A, Szabo M, Karanikas G, et al.: Imaging of advanced neuroendocrine tumors with 18F-FDOPA PET. J Nucl Med 2004;45:1161-1167.
21. Oberg K: Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 2001;47 40-53.
22. Frank M, Klose K, Wied M, et al.: Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-1387.
23. Moertel CG, Kefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1991;326:519-523.
24. Schell SR, Camp ER, Caridi JG, et al.: Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 2002;6:664-670.
25. Warner RR, Nowakowski FS, Mitty H: Outcome of Hepatic Artery Chemoembolization in the Treatment of Metastatic Carcinoid of the Liver. Presented at SIR 2003. Salt Lake City, CO. Abstract 198 JVIR Feb 2003. 14(S1-197) No 2.
26. Torrisi JR, Treat J, Zeman R, et al.: Radiotherapy in the management of pancreatic islet cell tumors. Cancer 1987;60:1226-1231.
27. 131I-MIBG therapy. Clin Oncol 2003;15:193-198.
28. 90Y-DOTATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2004;31:1038-1046.